

Formulary Update

November 2025

The following changes to the [Adult Medicines Formulary](#) have been agreed during the ADTC or sub-committee meetings since September 2025. Additions and deletions of medicines are based on submitted formulary appeals, new drug assessment requests or formulary section reviews. Changes in preferred brands are based on decisions by Prescribing Management Groups.

ADTC decisions relating to SMC assessments are published in alternate months and can be accessed [here](#)

Deletions	Indication	Adult Medicines Formulary entry/ rationale	
Additions	Indication	Adult Medicines Formulary entry/ rationale	
Changes in preferred medicines or brand	New preferred medicines or brand	Adult Medicines Formulary entry / rationale	
Other changes	Changes made	Adult Medicines Formulary entry/ rationale	
colecalfiferol	NHSGGC preferred brand stated as Stexerol D3 1000 IU	6.6.4	Formulary change request
Zoledronic acid i.v	Added for indication of osteoporosis treatment in post fragile hip fracture patients (male and female)	6.6.2	Formulary change request